RESUMEN
For more than 20 years, the Ethical, Legal, and Social Implications (ELSI) Program of the National Human Genome Research Institute has supported empirical and conceptual research to anticipate and address the ethical, legal, and social implications of genomics. As a component of the agency that funds much of the underlying science, the program has always been an experiment. The ever-expanding number of issues the program addresses and the relatively low level of commitment on the part of other funding agencies to support such research make setting priorities especially challenging. Program-supported studies have had a significant impact on the conduct of genomics research, the implementation of genomic medicine, and broader public policies. The program's influence is likely to grow as ELSI research, genomics research, and policy development activities become increasingly integrated. Achieving the benefits of increased integration while preserving the autonomy, objectivity, and intellectual independence of ELSI investigators presents ongoing challenges and new opportunities.
Asunto(s)
Genoma Humano/genética , National Human Genome Research Institute (U.S.)/ética , National Human Genome Research Institute (U.S.)/legislación & jurisprudencia , Política Pública , Pruebas Genéticas , Humanos , National Human Genome Research Institute (U.S.)/tendencias , Estados UnidosRESUMEN
There has been much progress in genomics in the ten years since a draft sequence of the human genome was published. Opportunities for understanding health and disease are now unprecedented, as advances in genomics are harnessed to obtain robust foundational knowledge about the structure and function of the human genome and about the genetic contributions to human health and disease. Here we articulate a 2011 vision for the future of genomics research and describe the path towards an era of genomic medicine.
Asunto(s)
Genética Médica/tendencias , Genoma Humano/genética , Genómica/tendencias , Emparejamiento Base , Asesoramiento Genético , Predisposición Genética a la Enfermedad , Genética Médica/educación , Genómica/educación , Proyecto Genoma Humano , HumanosRESUMEN
The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale cancer genome studies in tumours from 50 different cancer types and/or subtypes that are of clinical and societal importance across the globe. Systematic studies of more than 25,000 cancer genomes at the genomic, epigenomic and transcriptomic levels will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.
Asunto(s)
Genética Médica/organización & administración , Genoma Humano/genética , Genómica/organización & administración , Cooperación Internacional , Neoplasias/genética , Metilación de ADN , Análisis Mutacional de ADN/tendencias , Bases de Datos Genéticas , Genes Relacionados con las Neoplasias/genética , Genética Médica/tendencias , Genómica/tendencias , Humanos , Propiedad Intelectual , Mutación , Neoplasias/clasificación , Neoplasias/patología , Neoplasias/terapiaRESUMEN
The Human Microbiome Project (HMP), funded as an initiative of the NIH Roadmap for Biomedical Research (http://nihroadmap.nih.gov), is a multi-component community resource. The goals of the HMP are: (1) to take advantage of new, high-throughput technologies to characterize the human microbiome more fully by studying samples from multiple body sites from each of at least 250 "normal" volunteers; (2) to determine whether there are associations between changes in the microbiome and health/disease by studying several different medical conditions; and (3) to provide both a standardized data resource and new technological approaches to enable such studies to be undertaken broadly in the scientific community. The ethical, legal, and social implications of such research are being systematically studied as well. The ultimate objective of the HMP is to demonstrate that there are opportunities to improve human health through monitoring or manipulation of the human microbiome. The history and implementation of this new program are described here.
Asunto(s)
Bacterias , Tracto Gastrointestinal/microbiología , Metagenoma/genética , Boca/microbiología , National Institutes of Health (U.S.) , Piel/microbiología , Vagina/microbiología , Bacterias/clasificación , Bacterias/genética , Bacterias/aislamiento & purificación , Femenino , Humanos , Programas Nacionales de Salud , ARN Ribosómico 16S/genética , Análisis de Secuencia de ADN , Estados UnidosRESUMEN
Biomedical research has and will continue to generate large amounts of data (termed 'big data') in many formats and at all levels. Consequently, there is an increasing need to better understand and mine the data to further knowledge and foster new discovery. The National Institutes of Health (NIH) has initiated a Big Data to Knowledge (BD2K) initiative to maximize the use of biomedical big data. BD2K seeks to better define how to extract value from the data, both for the individual investigator and the overall research community, create the analytic tools needed to enhance utility of the data, provide the next generation of trained personnel, and develop data science concepts and tools that can be made available to all stakeholders.
Asunto(s)
Investigación Biomédica , Conjuntos de Datos como Asunto , National Institutes of Health (U.S.) , Investigación Biomédica Traslacional , Estados UnidosRESUMEN
We systematically generated large-scale data sets to improve genome annotation for the nematode Caenorhabditis elegans, a key model organism. These data sets include transcriptome profiling across a developmental time course, genome-wide identification of transcription factor-binding sites, and maps of chromatin organization. From this, we created more complete and accurate gene models, including alternative splice forms and candidate noncoding RNAs. We constructed hierarchical networks of transcription factor-binding and microRNA interactions and discovered chromosomal locations bound by an unusually large number of transcription factors. Different patterns of chromatin composition and histone modification were revealed between chromosome arms and centers, with similarly prominent differences between autosomes and the X chromosome. Integrating data types, we built statistical models relating chromatin, transcription factor binding, and gene expression. Overall, our analyses ascribed putative functions to most of the conserved genome.
Asunto(s)
Caenorhabditis elegans/genética , Cromosomas , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Genoma de los Helmintos , Anotación de Secuencia Molecular , Animales , Caenorhabditis elegans/crecimiento & desarrollo , Caenorhabditis elegans/metabolismo , Proteínas de Caenorhabditis elegans/genética , Proteínas de Caenorhabditis elegans/metabolismo , Cromatina/genética , Cromatina/metabolismo , Cromatina/ultraestructura , Cromosomas/genética , Cromosomas/metabolismo , Cromosomas/ultraestructura , Biología Computacional/métodos , Secuencia Conservada , Evolución Molecular , Redes Reguladoras de Genes , Genes de Helminto , Genómica/métodos , Histonas/metabolismo , Modelos Genéticos , ARN de Helminto/genética , ARN de Helminto/metabolismo , ARN no Traducido/genética , ARN no Traducido/metabolismo , Secuencias Reguladoras de Ácidos Nucleicos , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
The National Institutes of Health's Mammalian Gene Collection (MGC) project was designed to generate and sequence a publicly accessible cDNA resource containing a complete open reading frame (ORF) for every human and mouse gene. The project initially used a random strategy to select clones from a large number of cDNA libraries from diverse tissues. Candidate clones were chosen based on 5'-EST sequences, and then fully sequenced to high accuracy and analyzed by algorithms developed for this project. Currently, more than 11,000 human and 10,000 mouse genes are represented in MGC by at least one clone with a full ORF. The random selection approach is now reaching a saturation point, and a transition to protocols targeted at the missing transcripts is now required to complete the mouse and human collections. Comparison of the sequence of the MGC clones to reference genome sequences reveals that most cDNA clones are of very high sequence quality, although it is likely that some cDNAs may carry missense variants as a consequence of experimental artifact, such as PCR, cloning, or reverse transcriptase errors. Recently, a rat cDNA component was added to the project, and ongoing frog (Xenopus) and zebrafish (Danio) cDNA projects were expanded to take advantage of the high-throughput MGC pipeline.